喹诺酮类药物在下呼吸道感染中的临床应用

Quinolones for the treatment of lower respiratory tract infections

下呼吸道感染为最常见的感染性疾病,也是多器官功能衰竭重要合并症和致死原因。呼吸喹诺酮对重要的呼吸道感染病原菌如肺炎链球菌、流感嗜血杆菌、卡他莫拉菌和非典型呼吸道致病菌具有良好的抗菌活性,其药效学和药代动力学特点在治疗下呼吸道感染中具有独特的优势,各国临床治疗指南均将呼吸喹诺酮列为下呼吸道感染(LRTIs)经验治疗的选择药物之一。本文综述了近年来呼吸喹诺酮类药物以及新研发的治疗下呼吸道感染的喹诺酮类药物在临床治疗和系统评价的最新进展。

Lower respiratory tract infections（LRTIs） are the most common infectious disease as well as major complications and mortality causes of multiple organ failure morbidity. Respiratory quinolones have good antibacterial activity against dominant respiratory bacterial pathogens such as streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, and atypical pneumonia pathogens. The advantage of favorable pharmacodynamic and pharmacokinetic profile for the treatment of LRTIs places respiratory quinolones among the options for empirical treatment of LRTIs recommend by guidelines. This review describes recent advances on clinical researches regarding respiratory quinolones and new quinolones for treatment of LRTIs.